Hi Daniel,
There's no real way to increase the 40% cell transmission efficiency. I mean, 40% is a bit of a lower bound, but realistically with the PSI or with the Supersampler, you're at best going to get 50%. So, better to do your calculations with 40% and err on the side of caution.
I'm not sure I understand your other point about PBMC MDIPA+Barcoding. According to this, MDIPA is designed to stain 3M PBMCs or 270uL WB in one tube:
https://www.fluidigm.com/binaries/conte ... igm%3AfileI'm sure there's a little wiggle room there, but I wouldn't advise staining 500K or 10M in just one MDIPA tube, you'd be over or under-titered. If you have live-cell barcoded as a first step, then combined into a single sample, you would want to *then split* the combined BC sample into aliquots and stain in separate MDIPA tubes of 3M. Or, conversely, dissolve the MDIPA lyo reagents from however many tubes you need to use, combine to a single cocktail tube, and then use that to stain your single combined BC sample.
I strongly suggest that you discuss your assay plans/needs with your Fluidigm FAS: they may have internal info on the lower and upper bounds of cell number that you can stain per single MDIPA tube.
Additionally: when you barcode, each sample affects the other samples. This means that if you have 19 good samples and 1 really poor-quality sample, any clumping and/or streaking from that poor-quality sample affects all 20 samples, 19 good and 1 bad. This also means that if you have strongly varying sample types in a given combined BC sample, each sample's cell distribution will affect the acquisition distribution of the entire composite sample. As an extreme case, imagine that you had a B cell line sample and a T cell line sample. The combined sample would be 50/50 B/T, and you'd have to take that into account for your target number of acquired Ungated events. So, you'd have to acquire 250K events to get 125K T cell events.
You may have previous data from flow experiments that will inform you on likely cell distributions/frequencies in all your planned patient types. Use that as a way to "guess" how many cells in total you'll need to acquire from the composite BC sample in order to still reach the depth of profiling you want to achieve in *each* donor sample.
Mike